+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study



Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study



Qjm 104(2): 133-139



Although it is well known that aspirin causes gastroduodenal mucosal injury and that aspirin-induced gastroduodenal mucosal injury is often asymptomatic, the prevalence and independent factors for gastroduodenal mucosal injury have not been clarified in asymptomatic patients taking low-dose aspirin and gastroprotective agents. To clarify the prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents. Prospective observational study. We performed endoscopy in 150 asymptomatic patients taking low-dose aspirin and gastroprotective agents for at least 3 months. Gastroduodenal ulcers/erosions were observed in 37.3% [ulcers (4.0%); erosions (34.0%)]. Univariate logistic regression analyses showed that proton-pump inhibitor (PPI) use was negatively associated with gastroduodenal ulcers/erosions [odds ratio (OR) 0.35, 95% confidence interval (95% CI) 0.17-0.75, P=0.007]. A multivariate logistic regression analysis selected PPI use as the only independent factor for gastroduodenal ulcers/erosions (OR 0.35, 95% CI 0.14-0.86, P=0.02). None of the 53 patients with PPI use had any gastroduodenal ulcers, and 11 with standard-dose PPI use tended to have a lower prevalence of gastroduodenal erosions than 42 with low-dose PPI use (0% vs. 28.6%, P=0.052). Gastroduodenal ulcers/erosions were observed in about one-third of asymptomatic patients taking low-dose aspirin and gastroprotective agents, and PPI use was a negative independent factor for gastroduodenal ulcers/erosions in those patients. In addition, standard-dose PPI therapy might be more effective in the prevention of aspirin-induced gastroduodenal mucosal injury than low-dose PPI therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 055150902

Download citation: RISBibTeXText

PMID: 20870780

DOI: 10.1093/qjmed/hcq169


Related references

Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2. Bmc Research Notes 6: 116-116, 2013

Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Alimentary Pharmacology & Therapeutics 31(1): 143-149, 2010

Predictors of gastroduodenal erosions in patients taking low dose aspirin h pylori protects the stomach but not the duodenum. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 801, 2003

Should coronary patients chronically taking a low-dose of aspirin receive gastroprotective agents?. Revista Espanola de Cardiologia 54(12): 1361-1364, 2002

Prevalence of gastroduodenal mucosal injury in asymptomatic patients taking antiplatelet agents in Japan. International Journal of Clinical Pharmacology and Therapeutics 47(12): 722-725, 2010

Nonsteroidal anti-inflammatory drugs induce asymptomatic gastroduodenal ulcers in the Japanese population: A case-control study on its prevalence and the protective effect of anti-ulcer agents. Journal of Clinical Biochemistry and Nutrition 39(3): 143-150, 2006

Prevalence of gastric lesions (ulcers and/or erosions) and their relationship to possible stressfull factors in asymptomatic Quarter Horse foals: endoscopic survey. Brazilian Journal of Veterinary Research and Animal Science 35(1/6): 166-169, 1998

Prevention of gastroduodenal complications in patients taking low-dose aspirin. Gastroenterologie Clinique et Biologique 28 Spec No 3: C84-C89, 2004

Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study. British Journal of Clinical Pharmacology 80(3): 589-598, 2016

Clinical features of gastroduodenal ulcer in Japanese patients taking low-dose aspirin. Digestive Diseases and Sciences 55(8): 2270-2274, 2010

Comparison of teprenone and famotidine against gastroduodenal mucosal damage in patients taking low-dose aspirin. Journal of Gastroenterology and Hepatology 29 Suppl 4(): 11-15, 2015

Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. Journal of Clinical Biochemistry and Nutrition 47(1): 27-31, 2010

Helicobacter pylori as a risk factor for peptic ulcers in patients taking low-dose aspirin. Gastroenterology 112(4 SUPPL ): A133, 1997

Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scandinavian Journal of Gastroenterology 45(3): 292-298, 2010

Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Alimentary Pharmacology & Therapeutics 40(7): 780-795, 2014